Diraxim

Rifaximin is a non-systemic, broad-spectrum antibiotic derived from rifamycin, indicated for the treatment of traveler’s diarrhea, hepatic encephalopathy, and irritable bowel syndrome with diarrhea (IBS-D). It inhibits bacterial RNA synthesis by binding to the β-subunit of bacterial DNA-dependent RNA polymerase. Minimal systemic absorption limits systemic side effects.